Schizophrenia: Reversal of atypical antipsychotic drug-induced obesity and its related metabolic disorders

精神分裂症：逆转非典型抗精神病药物引起的肥胖及其相关代谢紊乱

• 批准号: nhmrc : 1027493
• 负责人: Dr Francesca Fernandez-Enright
• 金额: $ 41.33万
• 依托单位: University of Wollongong
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/schizophrenia-reversal-atypical-metabolic-disorders/110573
• 关键词: Schizophrenia; Reversal; atypical; antipsychotic; drug

Atypical antipsychotic drugs such as olanzapine are commonly used to treat mental illnesses such as schizophrenia. While these drugs are effective, their side effects of obesity and metabolic disorders are a major hurdle leading to a serious lack of compliance in taking medication. This project aims to develop better antipsychotic treatment with reduced side-effects including obesity and metabolic disorders for mental illness patients.

非典型抗精神病药物，如奥氮平，通常用于治疗精神分裂症等精神疾病。虽然这些药物是有效的，但它们的肥胖和代谢紊乱的副作用是导致服药严重缺乏依从性的主要障碍。该项目旨在为精神疾病患者开发更好的抗精神病药物，减少副作用，包括肥胖和代谢紊乱。